Skip to main content

Table 3 Effect of tolvaptan at baseline and during inhibition of the nitric oxide system on plasma concentration of sodium and potassium and plasma osmolality in a randomized, placebo-controlled, double-blind, crossover study of 19 healthy subjects

From: Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects

Periods

Baseline

L-NMMA

Post infusion

p (GLM-within)

0-90 min

90-120 min

120-150 min

150-180 min

180-210 min

p-sodium (mmol/l)

Placebo

140 ± 2

139 ± 1

139 ± 2**

139. ± 2

138 ± 2**

0.272

Tolvaptan

143 ± 2

143 ± 2

141 ± 3**

141 ± 2

141 ± 2*

P (Wilcoxon’s signed rank test)

0.001

0.001

0.002

0.001

0.001

 

p- osm (mosm/kg)

Placebo

285 ± 3

285 ± 4

283 ± 4**

284 ± 4**

283 ± 4***

0.352

Tolvaptan

291 ± 3

291 ± 3

291 ± 3

291 ± 3

290 ± 3

p (GLM between) <0.0001

p (paired t-test)

<0.001

<0.001

<0.001

<0.001

<0.001

 

p-potassium (mmol/l)

Placebo

3.8 ± 0.2

3.8 ± 0.3

3.9 ± 0.3

3.9 ± 0.2

3.8 ± 0.1

0.325

Tolvaptan

3.9 ± 0.2

3.9 ± 0.2

4.0 ± 0.2

4.0 ± 0.1

4.0 ± 0.1

p (Wilcoxon’s signed rank test)

0.028

0.117

0.272

0.929

0.430

 
  1. Data are shown as mean with ± SD or medians with ± interquartile range. General linear model (GLM) with repeated measures was performed for comparison within the group and intervention as between subjects factor. Post-hoc Bonferoni test (*) was used for comparison of infusion period 90–150 min vs baseline and post infusion period 150–210 vs baseline. Paired t-test or Wilcoxon signed rank test was used for comparison between treatment group at baseline vs during infusion period 90–150 min, and at baseline vs post infusion period 150 – 210 min. *p < 0.05; **p < 0.001;***p < 0.0001.